2023
DOI: 10.3389/fimmu.2023.1241543
|View full text |Cite
|
Sign up to set email alerts
|

Toxicity in combined therapies for tumours treatments: a lesson from BAG3 in the TME?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1
1

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 17 publications
0
0
0
Order By: Relevance
“…Ex vivo studies on mouse tissues showed that combo treatments were able to promote an immunostimulatory microenvironment along with a significant reduction of cancer fibrosis [105][106][107]. Further refinements and developments of the anti-BAG3 mAb-based therapies could hopefully contribute additional evidence of efficacy and safety of combined treatments and could allow tailoring and diversify the protocols for other solid tumors [108].…”
Section: Communications Breakdown Operated By Monoclonal Antibodiesmentioning
confidence: 99%
“…Ex vivo studies on mouse tissues showed that combo treatments were able to promote an immunostimulatory microenvironment along with a significant reduction of cancer fibrosis [105][106][107]. Further refinements and developments of the anti-BAG3 mAb-based therapies could hopefully contribute additional evidence of efficacy and safety of combined treatments and could allow tailoring and diversify the protocols for other solid tumors [108].…”
Section: Communications Breakdown Operated By Monoclonal Antibodiesmentioning
confidence: 99%